PrognomiQ
- Company typePrivate
- Founded2020
- HeadquartersSan Mateo, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
PrognomiQ firmographics
Firmographics- Name
- PrognomiQ
- Legal name
- PrognomIQ, Inc.
- Website
- https://prognomiq.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
PrognomiQ industry classification
Industry- Product category
- Clinical Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Proteomics & Mass Spectrometry Services (HLAGANAB), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where PrognomiQ is headquartered
LocationHeadquarters
- HQ city
- San Mateo
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PrognomiQ business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others, Marketing or Sales
Revenue model
- Diagnostic Test Products: Clinical-stage company developing multi-omics diagnostic test products for early cancer detection. Revenue model not yet established as products are in development.
Go-to-market motion1 record
Distribution channels1 record
PrognomiQ product offering
Product offeringCore offering
PrognomiQ develops and commercializes multi-omics-based in-vitro diagnostic (IVD) test products for the early detection of cancer and other complex diseases. Its first commercially launched product is the ProVue lung cancer early detection test (an IVD), built on a proprietary platform that combines proteomic, genomic, metabolomic, and other health data to discover and validate disease biomarkers. The tests are sold to healthcare providers and clinical laboratories serving patients at risk of cancer and other complex diseases.
Product overview
PrognomiQ is developing a portfolio of multi-omics test products anchored by its proprietary multi-omics platform. The platform generates proteomic data at unparalleled volumes and depth, complemented by genomic, metabolomic, and other health data. The company has launched its lung cancer early detection test (an IVD product), with additional multi-omics tests for early disease detection and monitoring of cancer and other diseases in development.
Differentiator
Problem solved
Functional benefit
Products and services
- ProVue Lung Cancer Early Detection Test (IVD) An in-vitro diagnostic (IVD) test designed for the early detection of lung cancer. Built on PrognomiQ's proprietary multi-omics platform that integrates proteomic, genomic, metabolomic, and other health data, the test is intended for use by healthcare providers and clinical laboratories serving patients at elevated risk of lung cancer, with the goal of enabling earlier intervention when cure rates are highest.
Quantifiable outcome
- Earlier detection enables treatment when cure rates remain high
- +2 more outcomes
Companies that use PrognomiQ
Customer profileSegments2 records
Ideal customer profiles1 record
PrognomiQ technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
PrognomiQ partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Seer, Inc.corePrognomiQ was spun out from Seer, Inc. using Seer's Proteograph product for multi-omics test development. Philip Ma, previously Chief Business Officer and President of Seer, founded PrognomiQ. Omid Farokhzad, CEO of Seer, serves as Chair of PrognomiQ's Board of Directors.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
PrognomiQ competitors and assessment
Company assessmentDirect peers
- GRAIL: GRAIL develops the Galleri multi-cancer early detection test using methylation-based liquid biopsy. Both PrognomiQ and GRAIL are pursuing early cancer detection through blood-based multi-analyte diagnostics targeting similar clinical use cases and patient populations.
- Exact Sciences: Exact Sciences markets Cologuard (CRC screening) and Oncotype DX, and acquired Thrive Earlier Detection. Direct competitor in the cancer screening and early detection diagnostic space with established commercial channels and reimbursement.
- Guardant Health: Guardant Health offers liquid biopsy tests including Guardant360 for advanced cancer and Reveal for MRD. Direct peer in blood-based cancer diagnostics with overlapping technology approach and target customers.
- Natera: Natera develops Signatera (tumor-informed MRD test) and other cell-free DNA-based oncology tests. Direct competitor in blood-based cancer diagnostics targeting similar provider and biopharma customers.
- InterVenn Biosciences: InterVenn Biosciences develops glycoproteomics-based diagnostics. Comparable to PrognomiQ in using advanced 'omics (glycoproteomics vs. multi-omics proteomics/genomics/metabolomics) for cancer detection and working with similar clinical lab infrastructure.
Broad incumbents
- Seer, Inc. Seer invented the Proteograph platform that PrognomiQ's multi-omics tests rely upon. Strategic parent/spinout partner and adjacent player in proteomics tools and services, with overlapping scientific leadership (Omid Farokhzad chairs both companies).
- Bruker Corporation: Bruker is a leading mass spectrometry and proteomics instrumentation provider and a major PrognomiQ investor. Broad incumbent in proteomics infrastructure whose instruments and reagents enable multi-omics workflows comparable to PrognomiQ's.
- Veracyte: Veracyte is a genomic diagnostics company (Afirma, Decipher, Percepta) focused on urologic, thyroid, and lung cancer. Direct overlap with PrognomiQ in lung cancer diagnostics and broader cancer-focused molecular testing markets.
Emerging players
- Olink Holding: Olink provides proteomics platforms (PEA technology) widely used in biomarker discovery and translational research. Comparable as an emerging proteomics platform enabling large-scale protein biomarker analysis for diagnostics and biopharma applications.
- Standard BioTools (formerly Fluidigm): Standard BioTools offers mass cytometry and multi-omics instrumentation used in biomarker research and translational workflows. Overlap with PrognomiQ in multi-omics technology platforms serving life science research and translational markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
PrognomiQ social profiles
Digital presencePrognomiQ financial estimates
Financial estimateRevenue estimate
Valuation estimate
PrognomiQ leadership team
Management profileNumber of profiles
Profiles8 records
PrognomiQ funding detail
Funding detailFunding overview
Funding rounds4 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PrognomiQ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PrognomiQ
What does PrognomiQ do?
PrognomiQ develops and commercializes multi-omics-based in-vitro diagnostic (IVD) test products for the early detection of cancer and other complex diseases. Its first commercially launched product is the ProVue lung cancer early detection test (an IVD), built on a proprietary platform that combines proteomic, genomic, metabolomic, and other health data to discover and validate disease biomarkers. The tests are sold to healthcare providers and clinical laboratories serving patients at risk of cancer and other complex diseases.
Is PrognomiQ a public or private company?
PrognomiQ is a private company. It is classified as venture growth investor backed and is currently operating.
When was PrognomiQ founded?
PrognomiQ was founded in 2020. It employs 11 to 50 people.
Where is PrognomiQ based?
PrognomiQ is headquartered in San Mateo, United States, in the North America region.
How does PrognomiQ make money?
One revenue line is on record: diagnostic Test Products.
Who are PrognomiQ's main competitors?
Direct peers on record are GRAIL, Exact Sciences, Guardant Health, Natera and InterVenn Biosciences. Broad incumbents are Seer, Inc., Bruker Corporation and Veracyte. Emerging players are Olink Holding and Standard BioTools (formerly Fluidigm).
Does PrognomiQ have an API?
No public API is recorded for PrognomiQ.
What industry is PrognomiQ in?
PrognomiQ's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 62151 and its SIC code is 2835.